Optimal use of tranexamic acid for total hip arthroplasty: A network meta-analysis

Byung-Ho Yoon¹, Tae-young Kim²*, Young Seung Ko³, Young-Kyun Lee⁴, Yong-Chan Ha⁵, Kyung-Hoi Koo⁶

¹ Department of Orthopaedic Surgery, Inje University College of Medicine, Seoul Paik Hospital, Seoul, Korea, ² Department of Orthopaedic Surgery, Konkuk University Medical Center, School of Medicine, Konkuk University, Seoul, Korea, ³ Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴ Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, South Korea

* syty-chan@hanmail.net

Abstract

Background
Tranexamic acid (TXA) has been demonstrated to minimize blood loss after total hip arthroplasty. There are three main routes: intravenous (IV), intra-articular (topical), and combined (IV and topical) but little consensus support which is most effective and safe. We performed network meta-analysis to assess the comparative efficacy and safety of three different administration routes of TXA.

Methods
Twenty-five randomized controlled trials (RCT) were evaluated. Interventions were classified as: combined, IV multiple, IV single, topical and placebo. The primary outcome was effectiveness (transfusion rate, total blood loss, and total drain out). The secondary outcome was safety, based on the incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE).

Results
A total of 2227 patients were included in the 5 categories: 564 IV single, 319 IV multiple, 398 topical, 120 combined, and 826 placebo. A network meta-analysis identified the most effective interventions in terms of reducing the need for transfusion as follows: combined = 98.2%, IV single = 54.0%, IV multiple = 78.6%, topical = 66.1%, placebo = 0.0%. Compared with placebo, the IV single, IV multiple, topical, and combined interventions showed no difference in the rate of occurrence of DVT and PE.

Conclusions
A network meta-analysis indicated that combined administration of TXA (IV and topical) was effective in reducing the transfusion rate after hip arthroplasty compared with IV or topical alone. As no high-risk patients were evaluated in the RCTs, it is not known whether the combined method is safer for patients susceptible to DVT or PE.
Introduction

Total hip arthroplasty (THA) provides excellent results in patients with end-stage hip disease. [1] However, blood loss during the procedure can be as much as 500 to 2000 ml, and the proportion of patients requiring transfusion range from 16% to 20%. [2, 3] To reduce blood loss and the need for transfusion, several prophylactic blood management protocols have been developed. [4]

Tranexamic acid (TXA), a synthesized anti fibrinolytic agent, inhibits the conversion of plasminogen to plasmin by competitively binding to the lysine-binding sites of plasminogen. [5] Thus, it effectively reduces postoperative bleeding by inhibiting fibrinolysis and clot degradation. Currently, six pairwise meta-analyses of clinical trials using THA have shown that TXA applied topically or intravenously can decrease blood loss and transfusion rate without an increased risk of complications. [6–11] However, the optimal administration route for TXA to achieve efficacy and safety after THA is still controversial. Methods of application include topical, intravenous (IV), and combined IV and topical. It is unclear which of these methods is most effective to reduce total blood loss and to reduce total drain out.

Traditional pair-wise meta-analysis can only address questions regarding pairs of treatments; therefore, they cannot determine which of the several interventions is most effective. A network meta-analysis (NMA) is a useful statistical method for comparing the efficacy of multiple therapies. Joint analysis of the data within a network framework allows novel inferences on treatment comparisons by combining direct and indirect evidence of all relative treatment effects with a common comparator. Combining the estimates of direct and indirect comparisons provides mixed estimates with maximum power and produces a relative ranking of all treatments for the studied outcome. [12]

We conducted an NMA to elucidate which method is most effective and safe during THA. We have also included up-to-date studies that were not used in previous meta-analyses in order to strengthen the evidence. The comparative efficacy and safety of TXA were investigated by comparing (1) transfusion rate, (2) total blood loss, (3) total drainage, (4) deep vein thrombosis (5), and pulmonary embolism.

Materials and methods

Search strategy

This study was conducted and reported based on guidelines and recommendations for network meta-analysis (S1 Table). [12] Searches of PubMed-Medline, Embase, and the Cochrane Library were performed in April 2017 using key terms (Hip OR arthroplasty OR replacement AND tranexamic acid). The detailed search strategies in each data base are presented in S2 Table. All trials had to be randomized, double-blinded, and controlled to ensure a minimum high level of quality, and study subjects with total hip arthroplasties. We also checked the reference lists of all potentially eligible studies and review papers to find any additional relevant publications.

Selection of studies

In the first stage of the study selection, two independent reviewers (YBH, KTY) first screened the titles and abstracts in order to identify relevant articles. To be included, patients had to have undergone total hip arthroplasty; no restriction was set regarding underlying causes or type of implant. The type of intervention had to include administration by IV, topical, or combined routes, or use of placebo. Outcome had to be measured using at least one of the following: rate of transfusion, total blood loss, total drain out, the incidence of deep venous
thrombosis and pulmonary embolism after THA. Studies that used other strategies to prevent blood loss were excluded, as were studies with less than 10 subjects or incomplete data, prospective non-randomized studies, and non-clinical studies (laboratory, animal, protocol, basic science, review). The language was restricted to English. When a published, updated study involving the same cohort of patients was identified, only the latest update was included in the analysis.

Data extraction
With respect to IV intervention, the protocols differed for each study. We classified them into two groups: 'IV single', in which TXA was injected only once; and 'IV multiple', in which TXA was injected more than twice. 'IV single' included single doses of: 10 mg/kg, 15 mg/kg, 1 g, and 3 g. 'IV multiple' included dual doses of: 10 mg/kg, 15 mg/kg bolus and infusion, a twice dose of 2 g, and a triple dose of 3 g. 'Combined' included IV 15 mg/kg bolus and 1 g topical injection; IV 1g bolus and 2g topical injection. The interventions were classified into five categories: IV single, IV multiple, topical, combined, and placebo.

For every eligible study, the following data were extracted and entered into a spreadsheet by the two reviewers: the first author, the year of publication, the number of patients, enrollment period, the mean age at the time of the operation, TXA treatment (route of administration, dose, bolus or continuous, single or multiple injection), the criteria for transfusion, the use of thromboprophylaxis, and the length of follow-up.

Quality assessment
All included articles were individually evaluated for risk of bias by two authors (YBH, KTY) respectively using the risk of bias assessment tool, as described in the Cochrane Handbook for Systematic Reviews of Interventions.

Data synthesis and analysis
Two types of statistical analyses were performed for the extracted data. The first was a pairwise meta-analysis of the included studies. For each study, we calculated the relative risks with a 95% confidence interval (CI) by using crude 2×2 tables, whenever possible, from the comparative studies[13]. The Mantel–Haenzel method was used to calculate the odds-ratio if there were zero values in any cell count in a table.[14] To evaluate the presence of clinical heterogeneity within pairwise comparisons, taking a conservative approach, heterogeneity between comparable studies was tested with chi-square (χ²) and I² tests. P > 0.1 and I² < 50% were the established criteria to determine the statistical heterogeneity.

A network meta-analysis was then conducted to determine comparative efficacy and safety. This type of analysis allowed us to utilize results from the comparison of two interventions with the same third intervention for indirect comparisons. For a given comparison, such as A versus B, direct evidence is provided by studies that compare two treatments directly (IV versus placebo) as in a standard direct pair-wise meta-analysis. In addition, indirect evidence for A versus B can be provided if studies that compare A versus C and B versus C are analyzed jointly (e.g., IV versus placebo studies and topical versus placebo studies can allow indirect comparison of IV versus topical via the use of placebo). All three interventions (IV, topical, and combined) had trial data compared with placebo. NMA aims to combine the direct and indirect evidence into a single-effect size and thereby increases the precision of the comparison. Valid results from NMA depend on the evidence network being internally consistent; direct and indirect sources of evidence should be in an agreement. A test of inconsistency was completed by using the loop-specific approach to evaluate heterogeneity and consistency of
the network. To rank the treatments according to safety or efficacy, we planned to use the surface under the cumulative ranking (SUCRA) probabilities, which are expressed as percentages of each intervention to an imaginary intervention that is always the best without uncertainty. For example, if combined administration had an 80% probability of superiority, this would be interpreted as follows: in 80% of the simulation runs, combined administration had the highest number of success rates out of all treatment modalities. Corresponding 95% credible intervals (CrIs) were obtained using the 2.5th and 97.5th percentiles of the posterior distribution.

All analyses were performed using STATA (version 14.0; Stata Corporation, College Station, TX, USA) with the “mvmeta” command[15] and self-programmed STATA routines, as described in Chaimani et al.[16] This study was exempted from institutional review board review because it did not involve human subjects.

Sensitivity analysis and publication bias
A sensitivity analysis was conducted by including only the studies that included transfusions with a strict transfusion strategy (hemoglobin level < 8 g/dl or < 9 g/dl in older patients with cardiopulmonary disease). In addition, we compared the overall results after excluding two studies[17, 18] that used “single 3 g” and “triple 3 g” treatments to evaluate whether the results were particularly influenced by studies using high-dose IVs. Finally the overall results were compared by excluding each one study that included combined treatment [19, 20] from the pool of the twenty-five studies. The publication bias for each complication was assessed visually by the adjusted network funnel plot.

Results
Description of included studies
We identified 25 RCTs. Twenty-one studies compared two interventions: 9 IV single vs placebo[21–29], 8 IV multiple vs placebo[17, 30–36], 3 compared topical application vs placebo [37–39], and 1 IV multiple vs topical.[40] Four studies had three comparative groups: IV single vs IV multiple vs placebo[41], IV single vs topical vs placebo[18], IV single vs combined vs placebo[19], and IV single vs topical vs combined.[20] A summary of the studies from a primary search of the databases to final inclusion or exclusion is displayed in the flowchart (Fig 1). A total of 2227 patients were included in the NMA: 564 IV single, 319 IV multiple, 398 topical, 120 combined, and 826 placebo. The majority of comparisons were between IV and placebo, but all direct comparisons between interventions were found, as can be seen in the network diagram (Fig 2, S1 Fig). When we integrated the evidence from all trials into the NMA, we found no inconsistency between direct and indirect evidence in all interventions. The characteristics of the included studies are summarized in Table 1.

Need for transfusion
Blood transfusion data were provided in all 25 studies. All four interventions effectively reduced transfusion compared with placebo; Combine (odds ratio (OR) = 0.04, 95% CI: 0.01–0.19, p<0.001), IV multiple (OR = 0.23, 95% CI: 0.15–0.35, p<0.001), topical use (OR = 0.30, 95% CI: 0.19–0.47, p<0.001), and IV single (OR = 0.34, 95% CI: 0.25–0.48, p<0.001). The combined method of TXA use significantly reduced the transfusion rate compared with IV single (OR = 0.10, 95% CI: 0.02–0.55, p = 0.008); IV multiple (OR = 0.16, 95% CI: 0.03–0.87, p = 0.034); and topical use (OR = 0.12, 95% CI: 0.02–0.64, p = 0.014) (Fig 3A). But no significant difference was observed across three interventions (IV single, IV multiple, and topical). The network meta-analysis showed the following probabilities ranked as the most effective
intervention with 95% CrIs: combined = 98.2%, IV multiple = 78.6%, topical = 66.1%, IV single = 54.0%, and placebo = 0.0% (Fig 4).

Total blood loss and total drain out
Eighteen trials[17–21, 23, 24, 27, 29–32, 35–38, 40, 41] involving a total of 1799 patients reported data for total blood loss. All interventions significantly reduced total blood loss compared with placebo; however, no difference was observed across the four non-placebo interventions (Fig 3B). Eleven trials[17, 19, 22–24, 29, 30, 35–38] with 827 patients reported data for total drain loss. There was no significant difference across four of the interventions (Fig 3C). The ranking of the five interventions with regards to total blood loss and drain out is summarized in Fig 4.

Deep vein thrombosis and pulmonary embolism
A total of 23 trials[17–23, 25, 27–41] with 1982 patients reported the data for DVT, and 18 trials[17–21, 23, 25, 27, 28, 30, 32–34, 36–40] with 1776 patients reported data for PE. In this analysis, placebo was used as the reference. No significant difference for the rate of DVT occurrence was observed for IV single (OR = 1.57, 95% CI: 0.64–3.83, p = 0.32); IV multiple (OR = 0.91, 95% CI: 0.34–2.46, p = 0.86); topical use (OR = 0.59, 95% CI: 0.20–1.78, p = 0.35); or combined use (OR = 2.08, 95% CI: 0.50–8.67, p = 0.31) compared with placebo; the results
were the same for PE (Fig 5). The ranking of the five interventions with regards to total blood loss and drain out is summarized in Fig 4.

**Sensitivity analysis**

The result of the sensitivity analysis, which included only studies in which transfusions were performed with a strict transfusion strategy or excluded two studies that used the “single 3 g” and “triple 3 g” routes, or excluded each one study that included combined treatment was similar to the results of our primary overall results. Odds ratios, standardized mean differences, and rankings did not change considerably.

**Literature quality assessment and publication bias**

In terms of the methodological quality, subjects were randomized using an established allocation sequence, and the investigators and research assistants were blinded to the allocation. However, it is unclear whether the trials that were included meet all of the quality assessment
| Group comparison | Transfusion patients | Transfusion trigger | Total blood loss | Total drain out | Deep vein thrombosis | Pulmonary embolism | The route and dose of tranexamic acid |
|------------------|----------------------|--------------------|-----------------|----------------|---------------------|--------------------|-------------------------------------|
| Fraval 2017      | B: IV twice          | B: 1/50 (2%)       | <8g/L           | NA             | B: 0/50 (0%)        | B: 0/50 (0%)       | Twice 15mg/Kg                      |
|                  | E: Placebo           | E: 6/51 (12%)      |                 |                | E: 0/51(0%)         | E: 0/51(0%)        |                                     |
| Barrachina 2016  | A: IV single         | A: 8/35 (23%)      | <8.5g/L         | NA             | A: 1/35(3%)         | NA                 | Single 15mg/Kg                     |
|                  | B: IV twice          | B: 4/36 (11%)      |                 |                | B: 1/36 (3%)        |                    | Twice 10mg/Kg                      |
|                  | E: Placebo           | E: 14/37 (39%)     |                 |                | E: 2/37 (5%)        |                    |                                     |
| Xie 216          | A: IV single         | A: 3/70 (4%)       | <7g/L           | NA             | A: 1/70 (1%)        | A: 0/70 (0%)       | Single 1.5g                        |
|                  | C: Topical           | C: 4/70 (6%)       |                 |                | C: 0/70 (0%)        | C: 0/70 (0%)       | Topical 3g                         |
|                  | D: Combine           | D: 0/70 (0%)       |                 |                | D: 2/70 (3%)        | D: 0/70 (0%)       | Combine 3g                         |
| Na 2016          | A: IV single         | A: 2/29 (7%)       | <8g/L           | NA             | NA                  | NA                 | Single 10mg/Kg                     |
|                  | E: Placebo           | E: 5/26 (19%)      |                 |                | E: 0/38 (0%)        | E: 0/38 (0%)       |                                     |
| North 2016       | B: IV twice          | B: 8/70 (11%)      | <7g/L           | NA             | B: 0/70 (0%)        | B: 1/70 (%)        | Twice 2g                           |
|                  | C: Topical           | C: 12/69 (17%)     |                 |                | C: 0/69 (0%)        | C: 0/69 (0%)       | Topical 2g                         |
| Wang 2016        | A: IV single         | A: 9/81(11%)       | <7g/L           | NA             | A: 1/81(1%)         | A: 0/81(0%)        | Single 10mg/Kg or Single 15mg/Kg   |
|                  | E: Placebo           | E: 10/38 (26%)     |                 |                | E: 0/38 (0%)        | E: 0/38 (0%)       |                                     |
| Yi 2016          | A: IV single         | A: 8/50 (16%)      | <7g/L           | NA             | A: 1003 (367)       | A:127 (92)         | Single 15mg/Kg                     |
|                  | D: Combine           | D: 1/50 (2%)       |                 |                | D: 836 (344)        | D:127 (114)        | Combine 3g                         |
|                  | E: Placebo           | E: 19/50 (38%)     |                 |                | E: 1221 (386)       | E:244 (146)        | E: 0/50 (0%)                       |
| Hsu 2015         | B: IV twice          | B: 2/30 (7%)       | <8g/L           | NA             | NA                  | B: 0/30 (0%)       | Twice 2g                           |
|                  | E: Placebo           | E: 9/30 (30%)      |                 |                | E: 0/30 (0%)        | E: 0/30 (0%)       |                                     |
| Wei 2014         | A: IV single         | A: 6/101 (6%)      | <9g/L           | NA             | A: 959 (422)        | NA                 | Single 3g                          |
|                  | C: Topical           | C: 6/102 (6%)      |                 |                | C: 963 (421)        | C: 1/102 (1%)      | Topical 3g                         |
|                  | E: Placebo           | E: 26/100 (26%)    |                 |                | E: 1364 (279)       | E: 0/100 (0%)      | E:0/100(0%)                        |
| Martin 2014      | C: IA                | C: 3/25 (12%)      | <7g/L           | NA             | NA                  | C: 0/25 (0%)       | Topical 2g                         |
|                  | E: Placebo           | E: 5/25 (20%)      |                 |                | E: 0/25 (0%)        | E: 0/25 (0%)       |                                     |
| Yue 2014         | C: Topical           | C: 3/52 (6%)       | <7g/L           | NA             | C: 346 (332)        | C: 1/52 (2%)       | Topical 3g                         |
|                  | E: Placebo           | E: 11/49 (22%)     |                 |                | E: 1256 (194)       | E: 297 (109)       | E: 0/49 (0%)                       |
|                  |                      |                    |                 |                | E: 297 (109)        | E: 0/49 (0%)       |                                     |
| Alshryda 2013    | C: Topical           | C: 10/80 (13%)     | NA              | C: 1617 (188)  | C: 2/80 (3%)        | C: 0/80 (0%)       | NA                                 |
|                  | E: Placebo           | E: 26/81 (32%)     |                 | C: 260 (188)   | E: 4/81 (5%)        | E: 0/81 (0%)       |                                     |
| Lee 2013         | B: IV twice          | B: 9/34 (26%)      | Hb loss >30%    | B: 647 (216)   | B: 0/34 (0%)        | NA                  | Twice 15mg/Kg                     |
|                  | E: Placebo           | E: 20/34 (59%)     |                 | E:1326 (349)   | E:0/34 (0%)         |                    |                                     |
| Kazemi 2010      | A: IV single         | A: 7/32 (22%)      | NA              | NA             | A: 0/32 (0%)        | A: 0/32 (0%)       | Single 15mg/Kg                     |
|                  | E: Placebo           | E: 15/32 (49%)     |                 | NA             | E: 1/32 (3%)        | E: 0/32 (0%)       |                                     |
| Rajesparan 2009  | A: IV single         | A: 3/36 (8%)       | NA              | A:1372 (436)   | A:1/36 (2%)         | A: 0/36 (0%)       | Single 1g                          |
|                  | E: Placebo           | E: 10/37 (27%)     |                 | E:1683 (705)   | E:2/37 (5%)         | E: 0/37 (0%)       |                                     |

(Continued)
Table 1. (Continued)

| Group comparison | Transfusion trigger | Total blood loss | The route and dose of tranexamic acid |
|------------------|---------------------|-----------------|--------------------------------------|
| Claeys 2007      | A: IV single        | A: 1/20 (5%)    | <8.5g/L NA A:352 (152) E:524 (244) A: 3/20 (15%) E:0/20 (0%) Single 15mg/Kg |
|                  | E: Placebo         | E: 6/20 (30%)   |                                      |                                      |
| Johansson 2005   | A: IV single        | A: 8/47 (17%)   | NA A:969 (434) D:1324 (577) D:528 (211) NA NA Single 15mg/Kg |
|                  | E: Placebo         | E: 23/53 (43%)  |                                      |                                      |
| Niskanen 2005    | A: IV single        | A: 5/19 (26%)   | NA A:626 (206) E:790 (293) E:312 (126) E: 0/20 (0%) E: 0/20 (0%) Three doses of 10mg/Kg |
|                  | E: Placebo         | E: 8/20 (40%)   |                                      |                                      |
| Garneti 2004     | A: IV single        | A: 16/25 (64%)  | NA A:1443 (809) A:411 (220) A: 0/25 (0%) A: 1/25 (4%) Single 10mg/Kg |
|                  | E: Placebo         | E: 14/25 (56%)  | E:1340 (665) E:353 (311) E: 0/25 (0%) E: 0/25 (0%) |
| Lemay 2004       | B: IV twice         | B: 6/20 (30%)   | <7g/L B:1308 (462) B:487 (234) B: 0/20 (0%) B: 0/20 (0%) Twice 10 mg/kg (bolus and infusion) |
|                  | E: Placebo         | E: 13/19 (68%)  | E:1469 (405) E:580 (290) E: 0/19 (0%) E: 0/19 (0%) |
| Yamasaki 2004    | A: IV single        | A: 0/20 (0%)    | NA A:1350 (477) A:655 (418) A: 0/20 (0%) NA Single 1g |
|                  | E: Placebo         | E: 0/20 (0%)    | E:1667 (401) E:890 (353) E: 0/20 (0%) |
| Husted 2003      | B: IV twice         | B: 2/20 (10%)   | Hb loss >25% NA NA B: 0/20 (0%) B: 0/20 (0%) Twice 10 mg/kg (bolus and infusion) |
|                  | E: Placebo         | E: 7/20 (35%)   |                                      | E: 0/20 (0%) E: 0/20 (0%) |
| Benoni 2001      | A: IV single        | A: 4/18 (22%)   | <10g/L A:759 (193) E:996 (267) NA A: 0/18 (0%) A: 0/18 (0%) Single 10mg/Kg |
|                  | E: Placebo         | E: 8/20 (40%)   |                                      | E: 0/20 (0%) E: 0/20 (0%) |
| Ekback 2000      | B: IV twice         | B: 1/20 (5%)    | Hct loss >27% B:1130 (400) E:1770 (523) NA B: 1/20 (5%) NA Twice 10mg/Kg |
|                  | E: Placebo         | E: 1/20 (5%)    | E:1469 (405) E:580 (290) E: 0/19 (0%) E: 0/19 (0%) |
| Benoni 2000      | B: IV twice         | B: 9/20 (45%)   | NA B:550 (275) A:440 (303) B: 3/20 (15%) B: 0/20 (0%) Twice 10mg/Kg |
|                  | E: Placebo         | E: 15/19 (79%)  | E:500 (234) E:450 (271) E: 3/19 (16%) E: 0/19 (0%) |
| Fraval 2017      | B: IV twice         | B: 1/50 (2%)    | <8.5g/L B: 0/50 (0%) B: 0/50 (0%) Twice 15mg/Kg |
|                  | E: Placebo         | E: 6/51 (12%)   | B: 1394 (426) E:0/51(0%) E: 0/51(0%) |
| Barrachina 2016  | A: IV single        | A: 8/35 (23%)   | <8.5g/L A:1377 (689) NA A: 1/35(3%) NA Single 15mg/Kg |
|                  | B: IV twice         | B: 4/36 (11%)   | A:1377 (689) NA A: 1/35(3%) NA Single 15mg/Kg |
|                  | E: Placebo         | E: 14/37 (39%)  |                                      |                                      |
| Xie 216          | A: IV single        | A: 3/70 (4%)    | <7g/L A: 887 (686) C: 905 (238) D: 2/70 (3%) D: 0/70 (0%) Single 1.5g |
|                  | C: Topical          | C: 4/70 (6%)    | C: 878 (686) C: 905 (238) C: 0/70 (0%) C: 0/70 (0%) |
|                  | D: Combine          | D: 0/70 (0%)    | D: 905 (238) D: 777 (189) D: 0/70 (0%) D: 0/70 (0%) |
| Na 2016          | A: IV single        | A: 2/29 (7%)    | <8g/L NA NA NA NA Single 10mg/Kg |
|                  | E: Placebo         | E: 5/26 (19%)   |                                      |                                      |
| North 2016       | B: IV twice         | B: 8/70 (11%)   | <7g/L B: 1195 (486) B: 0/70 (0%) B: 1/70 (%) Twice 2g |
|                  | C: Topical          | C: 12/69 (17%)  | B: 1195 (486) C: 1443 (563) C: 0/69 (0%) |
|                  | D: Combine          | D: 0/70 (0%)    | D: 1195 (486) D: 1443 (563) D: 0/70 (0%) D: 0/70 (0%) |
| Wang 2016        | A: IV single        | A: 9/81 (11%)   | <7g/L NA NA A: 1/81 (1%) A: 0/81 (0%) Single 10mg/Kg or Single 15mg/Kg |
|                  | E: Placebo         | E: 10/38 (26%)  | E: 0/38 (0%) E: 0/38 (0%) |

(Continued)
Table 1. (Continued)

| Group comparison | Transfusion (patients) | Transfusion trigger | Total blood loss | Total drain out | Deep vein thrombosis | Pulmonary embolism | The route and dose of tranexamic acid |
|------------------|-----------------------|--------------------|-----------------|----------------|----------------------|-------------------|-------------------------------------|
| Yi 2016          | A: IV single          | 8/50 (16%)         | <7g/L           |               | A: 1003 (367)        | A: 2/50 (4%)       | Single 15mg/Kg                     |
|                  | D: Combine            | 1/50 (2%)          |                 |               | D: 836 (344)         | D: 2/50 (4%)       | Combine 3g                         |
|                  | E: Placebo            | 19/50 (38%)        |                 |               | E: 1221 (386)        | E: 244 (146)       |                                      |
| Hsu 2015         | B: IV twice           | 2/30 (7%)          | <8g/L           | NA            |                      | B: 0/30 (0%)       | Twice 2g                            |
|                  | E: Placebo            | 9/30 (30%)         |                 | NA            |                      | E: 0/30 (0%)       |                                      |
| Wei 2014         | A: IV single          | 6/101 (6%)         | <9g/L           | NA            | A: 959 (422)         | A: 1/101 (1%)      | Single 3g                           |
|                  | C: Topical            | 6/102 (6%)         |                 |               | C: 963 (421)         | C: 1/102 (1%)      | Topical 3g                          |
|                  | E: Placebo            | 26/100 (26%)       |                 |               | E: 1364 (279)        | E: 0/100 (0%)      |                                      |
| Martin 2014      | C: IA                 | 3/25 (12%)         | <7g/L           | NA            |                      | C: 0/25 (0%)       | Topical 2g                          |
|                  | E: Placebo            | 5/25 (20%)         |                 | NA            |                      | E: 0/25 (0%)       |                                      |
| Yue 2014         | C: Topical            | 3/52 (6%)          | <7g/L           | NA            | C: 346 (332)         | C: 1/52 (2%)       | Topical 3g                          |
|                  | E: Placebo            | 11/49 (22%)        |                 |               | E: 1256 (194)        | E: 0/49 (0%)       |                                      |
| Akhrysa 2013     | C: Topical            | 10/80 (13%)        | NA              |               | C: 1617 (188)        | C: 2/80 (3%)       | NA                                  |
|                  | E: Placebo            | 26/81 (32%)        |                 |               | E: 1981 (1007)       | E: 4/81 (5%)       |                                      |
| Lee 2013         | B: IV twice           | 9/34 (26%)         | HB loss >30%    | B:647 (216)   | B:439 (172)          | B: 0/34 (0%)       | Twice 15mg/Kg                       |
|                  | E: Placebo            | 20/34 (59%)        |                 | E:1326 (349)  | E:1074 (287)         | E: 0/34 (0%)       |                                      |
| Kazemi 2010      | A: IV single          | 7/32 (22%)         | NA              |               | NA                   | A: 0/32 (0%)       | Single 15mg/Kg                     |
|                  | E: Placebo            | 15/32 (49%)        |                 |               | NA                   | E: 1/32 (3%)       |                                      |
| Rajesparan 2009  | A: IV single          | 3/36 (8%)          | NA              |               | A:1372 (436)         | A: 1/36 (2%)       | Single 1g                           |
|                  | E: Placebo            | 10/37 (27%)        |                 |               | E:1683 (705)         | E: 2/37 (5%)       |                                      |
| Claeyss 2007     | A: IV single          | 1/20 (5%)          | <8.5g/L         | NA            | A:352 (152)          | A: 3/20 (15%)      | Single 15mg/Kg                     |
|                  | E: Placebo            | 6/20 (30%)         |                 |               | E:524 (244)          | E: 0/20 (0%)       |                                      |
| Johansson 2005   | A: IV single          | 8/47 (17%)         | NA              |               | A:969 (434)          | A:350 (114)        | Single 15mg/Kg                     |
|                  | E: Placebo            | 23/53 (43%)        |                 |               | D:1324 (577)         | D:528 (211)        |                                      |
| Niskanen 2005    | A: IV single          | 5/19 (26%)         | NA              |               | A:626 (206)          | A:166 (75)         | Three doses of 10mg/Kg              |
|                  | E: Placebo            | 8/20 (40%)         |                 |               | E:790 (293)          | E:312 (126)        |                                      |
| Garnet 2004      | A: IV single          | 16/25 (64%)        | NA              |               | A:1443 (809)         | A:411 (220)        | Single 10mg/Kg                     |
|                  | E: Placebo            | 14/25 (56%)        |                 |               | E:1340 (665)         | E:353 (311)        |                                      |
| Lemay 2004       | B: IV twice           | 6/20 (30%)         | <7g/L           | B:1308 (462)  | B:487 (234)          | B: 0/20 (0%)       | Twice 10 mg/kg (bolus and infusion) |
|                  | E: Placebo            | 13/19 (68%)        |                 | E:1469 (405)  | E:580 (290)          | E: 0/19 (0%)       |                                      |
| Yamasaki 2004    | A: IV single          | 0/20 (0%)          | NA              |               | A:1350 (477)         | A:655 (418)        | Single 1g                           |
|                  | E: Placebo            | 0/20 (0%)          |                 |               | E:1667 (401)         | E:890 (353)        |                                      |
| Husted 2003      | B: IV twice           | 2/20 (10%)         | HB loss >25%    | NA            |                      | B: 0/20 (0%)       | Twice 10 mg/kg (bolus and infusion) |
|                  | E: Placebo            | 7/20 (35%)         |                 |               | E: 0/20 (0%)         |                                      |
| Benoni 2001      | A: IV single          | 4/18 (22%)         | <10g/L          | A:759 (193)   | NA                   | A: 0/18 (0%)       | Single 10mg/Kg                     |
|                  | E: Placebo            | 8/20 (40%)         |                 | E:996 (267)   | E: 0/20 (0%)         |                                      | (Continued)
criteria (S2 Fig). Based on the adjusted funnel plot there was no evidence of publication bias for the set of studies related to each results (S3 to S7 Figs).

**Discussion**

The use of TXA in joint arthroplasty is becoming more prevalent for minimizing perioperative blood loss and the need for transfusion because it has been shown to provide both clinical and cost-saving benefits.[42] Surgeons may choose to use TXA intravenously, topically, or a combination of the two. Recently, many meta-analyses have been performed to analyze which route of use for TXA is most beneficial. This has not been fully clarified yet because the previous meta-analyses conducted a pair-wise comparison based only on direct evidence. To our knowledge, this is the first attempt to integrate all of the evidence regarding different routes in TXA use for THA in an NMA.

A combined methodology for TXA treatment (IV and topical) is an emerging method for enhancing the hemostasis effects of TXA when performing total joint arthroplasty.[20] Our meta-analysis indicated that the combined use of TXA resulted in a significantly reduced transfusion rate compared with IV or topical use alone. This outcome concurs with a recent meta-analysis that showed combined IV and topical TXA as being more effective for hemostasis compared with IV alone; however, this analysis included only eight RCTs with a total of 850 patients.[6] Our study combined direct and indirect evidence from 25 RCTs involving 2227 patients who underwent THA to estimate the relative efficacy of all routes of TXA.

In our NMA, 'IV multiple' use reduced total blood loss compared with IV single, but the difference was not significant. This result suggests that despite greater efficacy with increased dosage, doses in excess of the effective dose confer no significant additional benefit.[43] In high risk patient, such as patients with upper gastrointestinal bleeding, they may use up to 4 grams per day.[44] But even in case of drug with high therapeutic indexes, clinicians should strive to administer the minimum dose to reach a desired goal. Depending on the expected degree of bleeding and the patient’s condition, it may be possible to consider using different routes.

Our results showed that the IV single, IV multiple, and topical treatments were equivalent for all outcome measurements. We paid special attention to whether the effect of topical TXA has a greater effect on total drain out than total blood loss, although the doses used were comparable to those of IV use. However, there was no significant difference between the two groups with respect to the total drain out. It is suggested that there was no effect on the intraoperative blood loss because TXA delayed lysis of the fibrin clot by the proteolytic action of the plasmin, rather than by influencing primary hemostasis and coagulation.[27]

There were no significant differences across all interventions, including placebo, for incidence of DVT and PE, thus confirming the safety of TXA use. Topical application, or small doses of TXA, are used to avoid systemic complications. TXA is known to not suppress the

| Group comparison | Transfusion (patients) | Transfusion trigger | Total blood loss | Total drain out | Deep vein thrombosis | Pulmonary embolism | The route and dose of tranexamic acid |
|------------------|------------------------|--------------------|-----------------|-----------------|----------------------|-------------------|-----------------------------------|
| Ekback 2000      | B: IV twice            | B: 1/20 (5%)       | Hct loss >27%   | B:1130 (400)   | NA                   | B: 1/20 (5%)       | NA                  | Twice 10mg/Kg                     |
|                  | E: Placebo             | E: 1/20 (5%)       |                 | E:1770 (523)   | E: 1/20 (5%)         |                   |                                   |
| Benoni 2000      | B: IV twice            | B: 9/20 (45%)      | NA              | B:550 (275)    | A:440 (303)          | B: 3/20 (15%)      | B: 0/20 (0%)                     | Twice 10mg/Kg                     |
|                  | E: Placebo             | E: 15/19 (79%)     |                 | E:500 (234)    | E:450 (271)          | E: 3/19 (16%)      | E: 0/19 (0%)                     |                                   |

IV: intravenous, NA: non-available, Hb: hemoglobin, Hct: hematocrit

https://doi.org/10.1371/journal.pone.0206480.t001
Optimal use of tranexamic acid for total hip arthroplasty

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| IV multiple      | 0.66 (0.38, 1.13) (0.37, 1.19) |
| Topical          | 0.88 (0.52, 1.49) (0.50, 1.56) |
| Combine          | 0.10 (0.02, 0.59) (0.02, 0.64) |
| Placebo          | 2.92 (2.09, 4.06) (2.03, 4.18) |

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| Topical          | 1.33 (0.76, 2.32) (0.72, 2.43) |
| Combine          | 0.16 (0.03, 0.87) (0.02, 0.10) |
| Placebo          | 4.39 (2.83, 6.81) (2.72, 7.08) |

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| Placebo vs combine | 28.15 (5.32, 148.99) (4.60, 172.38) |

p value for network consistency = 0.655

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| IV multiple      | 0.80 (0.52, 1.24) (0.27, 2.34) |
| Topical          | 0.99 (0.65, 1.52) (0.34, 2.90) |
| Combine          | 0.62 (0.35, 1.09) (0.20, 1.97) |
| Placebo          | 1.98 (1.45, 2.71) (0.72, 5.46) |

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| Topical          | 1.24 (0.78, 1.98) (0.41, 3.70) |
| Combine          | 0.78 (0.40, 1.49) (0.23, 2.82) |
| Placebo          | 2.48 (1.76, 3.53) (0.89, 6.93) |

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| Placebo vs combine | 3.20 (1.79, 5.71) (1.00, 10.26) |

p value for network consistency = 0.996

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| IV multiple      | 0.64 (0.23, 1.82) (0.06, 6.54) |
| Topical          | 0.92 (0.26, 3.19) (0.08, 11.01) |
| Combine          | 0.85 (0.23, 3.21) (0.07, 10.99) |
| Placebo          | 1.92 (0.97, 3.79) (0.24, 15.28) |

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| Topical          | 1.42 (0.39, 5.25) (0.11, 18.01) |
| Combine          | 1.32 (0.28, 6.19) (0.09, 20.64) |
| Placebo          | 2.98 (1.36, 6.53) (0.35, 25.24) |

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| Placebo vs combine | 0.93 (0.17, 5.02) (0.05, 16.87) |
|                  | 2.09 (0.74, 5.92) (0.21, 21.23) |

| Treatment Effect | Mean with 95%CI and 95%PrI |
|------------------|----------------------------|
| Placebo vs combine | 2.25 (0.60, 8.50) (0.17, 29.08) |

p value for network consistency = 0.645

p value for network consistency = 0.655

p value for network consistency = 0.996

p value for network consistency = 0.645
fibrinolytic activity in normal vessel walls, which is the most important link in the fibrinolytic defense system.\cite{45} This is the most potent reason why IV TXA will not increase the occurrence of DVT after THA. All of the RCTs that we evaluated excluded high-risk patients for thrombosis, such as those with a history of ischemic heart disease, cerebrovascular disease, or thromboembolic disease. Thus, it is necessary to confirm whether combined TXA is safe in patients who are susceptible to these types of events, although our study demonstrated that TXA safely reduces the transfusion rate without thromboembolic risk.

Our study was carefully designed to reduce bias, but several limitations remain. First, with regards to the TXA, the variation in regimens between the studies might cause heterogeneity. To clarify this issue, we classified IV use into IV single and IV multiple. Second, differences in the transfusion criteria, surgical approaches, and postoperative blood saving measures, patient age, as well as the protocols for thromboprophylaxis may have influenced the results. However, the OR values are meaningful as they have been calculated using the same protocol within each study.
In summary, compared with topical and IV TXA use, combined TXA treatment can decrease the transfusion requirement without an increased risk of complications (DVT and PE). The topical administration alone of TXA did not decrease total drain out and had a similar effect when compared with IV administration. Surgeons might consider using combine TXA treatment when there may be tendency for bleeding or a difficult surgery. However, it has not been confirmed that this is safe for patients who are susceptible to DVT or PE. Randomized trials are needed to clarify the optimal dosing and time to administration of TXA.

Supporting information

S1 Table. Updated checklist for network meta-analysis of randomized clinical trials. (DOCX)

S2 Table. The search strategy that details the searching process of relevant clinical study selection. (DOCX)

S1 Fig. Contributions matrix: percentage contribution of each direct estimate to the network meta-analysis estimates for preventing blood transfusions. In these matrices, the size of each square is proportional to the weight attached to each direct summary effect. A: IV single B: IV multiple C: topical D: combined E: placebo. (TIFF)

S2 Fig. Risk of graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies. (TIFF)

S3 Fig. Adjusted funnel plot for network meta-analysis of need for blood transfusion. (TIF)

S4 Fig. Adjusted funnel plot for network meta-analysis of total blood loss. (TIF)

S5 Fig. Adjusted funnel plot for network meta-analysis of total drain out. (TIF)
S6 Fig. Adjusted funnel plot for network meta-analysis of deep vein thrombosis. (TIF)

S7 Fig. Adjusted funnel plot for network meta-analysis of pulmonary embolism. (TIF)

Author Contributions

**Conceptualization:** Byung-Ho Yoon, Tae-young Kim, Young-Kyun Lee, Yong-Chan Ha, Kyung-Hoi Koo.

**Data curation:** Byung-Ho Yoon, Tae-young Kim, Young Seung Ko, Young-Kyun Lee, Yong-Chan Ha, Kyung-Hoi Koo.

**Formal analysis:** Byung-Ho Yoon, Tae-young Kim, Young Seung Ko, Young-Kyun Lee, Yong-Chan Ha, Kyung-Hoi Koo.

**Funding acquisition:** Tae-young Kim, Kyung-Hoi Koo.

**Investigation:** Byung-Ho Yoon, Young Seung Ko.

**Methodology:** Byung-Ho Yoon, Tae-young Kim, Young Seung Ko, Young-Kyun Lee, Yong-Chan Ha, Kyung-Hoi Koo.

**Project administration:** Byung-Ho Yoon.

**Resources:** Tae-young Kim.

**Software:** Byung-Ho Yoon.

**Supervision:** Byung-Ho Yoon, Tae-young Kim, Young-Kyun Lee, Yong-Chan Ha, Kyung-Hoi Koo.

**Validation:** Byung-Ho Yoon, Tae-young Kim, Young Seung Ko, Young-Kyun Lee, Yong-Chan Ha, Kyung-Hoi Koo.

**Visualization:** Byung-Ho Yoon, Tae-young Kim, Young Seung Ko, Young-Kyun Lee, Yong-Chan Ha.

**Writing – original draft:** Byung-Ho Yoon, Tae-young Kim, Young Seung Ko.

**Writing – review & editing:** Byung-Ho Yoon, Young-Kyun Lee, Yong-Chan Ha, Kyung-Hoi Koo.

References

1. Spencer-Gardner L, Pierrépont J, Topham M, Bare J, McMahon S, Shimmin AJ. Patient-specific instrumentation improves the accuracy of acetabular component placement in total hip arthroplasty. Bone Joint J. 2016; 98-B(10):1342–6. Epub 2016/10/04. https://doi.org/10.1302/0301-620X.98B10.37808 PMID: 27694587.

2. Helder CW, Schwartz BE, Redondo M, Piponov HI, Gonzalez MH. Blood Transfusion After Primary Total Hip Arthroplasty: National Trends and Perioperative Outcomes. J Surg Orthop Adv. 2017; 26 (4):216–22. Epub 2018/02/21. PMID: 29461193.

3. Gwam CU, Mistry JB, Etcheson JI, George NE, Connors GP, Thomas M, et al. Decline in allogeneic blood transfusion usage in total hip arthroplasty patients: National Inpatient Sample 2009 to 2013. Hip Int. 2017:0. Epub 2017/12/09. https://doi.org/10.5301/hipint.5000590 PMID: 29218687.

4. Song JH, Park JW, Lee YK, Kim IS, Nho JH, Lee KJ, et al. Management of Blood Loss in Hip Arthroplasty: Korean Hip Society Current Consensus. Hip Pelvis. 2017; 29(2):81–90. Epub 2017/06/15. https://doi.org/10.5371/hp.2017.29.2.81 PMID: 28611958; PubMed Central PMCID: PMCPMC5465399.
5. Hallstrom B, Singal B, Cowen ME, Roberts KC, Hughes RE. The Michigan Experience with Safety and Effectiveness of Tranexamic Acid Use in Hip and Knee Arthroplasty. The Journal of bone and joint surgery American volume. 2016; 98(19):1646–55. Epub 2016/10/07. https://doi.org/10.2106/JBJS.15.01010 PMID: 27707851.

6. Zhang H, He G, Zhang C, Xu B, Wang X, Zhang C. Is combined topical and intravenous tranexamic acid superior to intravenous tranexamic acid alone for controlling blood loss after total hip arthroplasty?: A meta-analysis. Medicine (Baltimore). 2017; 96(21):e6916. Epub 2017/05/26. https://doi.org/10.1097/MD.0000000000005691 PMID: 28538381; PubMed Central PMCID: PMCPMC5457861.

7. Zhang P, Liang Y, Chen P, Fang Y, He J, Wang J. Intravenous versus topical tranexamic acid in primary total hip replacement: A meta-analysis. Medicine (Baltimore). 2016; 95(50):e5573. Epub 2016/12/16. https://doi.org/10.1097/md.0000000000005573 PMID: 27977590; PubMed Central PMCID: PMCPMC5268036.

8. Moskal JT, Capps SG. Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty. Orthopedics. 2016; 39(5):e883–92. Epub 2016/06/02. https://doi.org/10.3928/01477447-20160526-02 PMID: 27248332.

9. Zhu J, Zhu Y, Lei P, Zeng M, Su W, Hu Y. Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials. Medicine (Baltimore). 2017; 96(52):e9552. Epub 2018/02/01. https://doi.org/10.1097/MD.0000000000009552 PMID: 29384974.

10. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS one. 2013; 8(10):e76654. https://doi.org/10.1371/journal.pone.0076654 PMID: 24098547; PubMed Central PMCID: PMCPM378683.

11. Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. Acta Orthop. 2005; 76(5):442–8. Epub 2001/12/01. https://doi.org/10.1080/000164701753532754 PMID: 16470437.

12. Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. The Journal of arthroplasty. 2014; 29(11):2113–6. Epub 2014/08/27. https://doi.org/10.1016/j.arth.2014.07.019 PMID: 25155138.

13. Yi Z, Bin S, Jing Y, Zongke Z, Pengde K, Fuxing P. Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial of Intravenous Combined with Topical Versus Single-Dose Intravenous Administration. J Bone Joint Surg Am. 2016; 98(12):983–91. Epub 2016/06/17. https://doi.org/10.1099/000164701753532754 PMID: 27307358.

14. Xie J, Ma J, Yue C, Kang P, Pei F. Combined use of intravenous and topical tranexamic acid following cementless total hip arthroplasty: a randomized controlled trial. Hip Int. 2016; 26(1):36–42. Epub 2015/09/24. https://doi.org/10.5301/hipint.5000291 PMID: 26391263.

15. Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand. 2001; 72(5):442–8. Epub 2001/12/01. https://doi.org/10.1080/000164701753532754 PMID: 11790869.

16. Claeyts MA, Vermeersch N, Haentjens P. Reduction of Blood Loss with Tranexamic Acid in Primary Total Hip Replacement Surgery. Acta Chirurgica Belgica. 2016; 107(4):397–401. https://doi.org/10.1080/00015458.2007.11680081
23. Garneti N, Field J. Bone bleeding during total hip arthroplasty after administration of tranexamic acid. The Journal of arthroplasty. 2004; 19(4):488–92. https://doi.org/10.1016/j.arth.2003.12.073 PMID: 15188109

24. Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005; 76(3):314–9. Epub 2005/09/15. PMID: 16156456.

25. Kazemi SM, Mosaffa F, Eajazi A, Kaffashi M, Besheli LD, Bigdeli MR, et al. The Effect of Tranexamic Acid on Reducing Blood Loss in Cementless Total Hip Arthroplasty Under Epidural Anesthesia. Orthopededics. 2010; 33(1):17–22. https://doi.org/10.3928/01477447-20091124-30 PMID: 20055345

26. Na HS, Shin HJ, Lee YJ, Kim JH, Koo KH, Do SH. The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM(R)) analysis. Anaesthesia. 2016; 71(1):67–75. Epub 2015/11/13. https://doi.org/10.1111/anae.13270 PMID: 26559015.

27. Rajesparan K, Biant LC, Ahmad M, Field RE. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br. 2009; 91(6):776–83. Epub 2009/06/02. https://doi.org/10.1302/0301-620X.91B6.22393 PMID: 19483232.

28. Wang C, Kang P, Ma J, Yue C, Xie J, Pei F. Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses. Thromb Res. 2016; 141:119–23. Epub 2016/03/27. https://doi.org/10.1016/j.thromres.2016.02.027 PMID: 27016618.

29. Yamasaki S, Masuhara K, Fuji T. Tranexamic acid reduces blood loss after cementless total hip arthroplasty: rotational thromboelastograph ic (ROTEM(R)) analysis. Anaesthesiology. 2009; 110(2):151–8. Epub 2009/02/04. https://doi.org/10.1095/anaesthesia.2009.0908 PMID: 19260449.

30. Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexam ic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand. 2000; 71(3):250–4. Epub 2000/08/05. https://doi.org/10.1080/000164700317411834 PMID: 10919295.

31. Ekback G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckstrom J, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg. 2000; 91(5):1124–30. Epub 2000/10/26. PMID: 11049894.

32. Fraval A, Effeny P, Fiddelaers L, Smith B, Towell B, Tran P. OBTAIN A: Outcome Benefits of Tranexamic Acid in Hip Arthroplasty. A Randomized Double-Blind Controlled Trial. The Journal of arthroplasty. 2017; 32(5):1516–9. Epub 2017/01/17. https://doi.org/10.1016/j.arth.2016.11.045 PMID: 28089468.

33. Husted H, Blond L, Sonne-Holm S, Holm G, Jacobsen TW, Gebuhr P. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study. Bone Joint J. 2015; 97-B(7):905–10. Epub 2015/07/02. https://doi.org/10.1302/0301-620X.97B7.35029 PMID: 26130344.

34. Husted H, Blond L, Sonne-Holm S, Holm G, Jacobsen TW, Gebuhr P. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients. Acta Orthop Scand. 2003; 74(6):665–9. Epub 2004/02/07. https://doi.org/10.1080/00016470310018171 PMID: 14763696.

35. Lee YC, Park SJ, Kim JS, Cho CH. Effect of tranexamic acid on reducing postoperative blood loss in combined hypotensive epidural anesthesia and general anesthesia for total hip replacement. J Clin Anesth. 2013; 25(5):393–8. Epub 2013/08/24. https://doi.org/10.1016/j.jclinane.2013.02.006 PMID: 23965206.

36. Lemay E, Guay J, Cote C, Roy A. Tranexamic acid reduces the need for allogenic red cell transfusions in patients undergoing total hip replacement. Can J Anaesth. 2004; 51(1):31–7. Epub 2004/01/08. https://doi.org/10.1007/BF03018543 PMID: 14709457.

37. Yue C, Kang P, Yang P, Xie J, Pei F. Topical application of tranexamic acid in primary total hip arthroplasty: a randomized double-blind controlled trial. The Journal of arthroplasty. 2014; 29(12):2452–6. Epub 2014/05/06. https://doi.org/10.1016/j.arth.2014.03.032 PMID: 24793893.

38. Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H, et al. Topical (Intra-Articular) Tranexamic Acid Reduces Blood Loss and Transfusion Rates Following Total Hip Replacement. The Journal of Bone and Joint Surgery-American Volume. 2013; 95(21):1969–74. https://doi.org/10.2106/JBJS.L.00908 PMID: 24196467.

39. Martin JG, Cassatt KB, Kincaid-Cinnamon KA, Westendorf DS, Garton AS, Lemke JH. Topical administration of tranexamic acid in primary hip total and hip total knee arthroplasty. The arthroplasty. 2014; 29(5):889–94. Epub 2013/11/19. https://doi.org/10.1016/j.arth.2013.10.005 PMID: 24238825.

40. North WT, Mehran N, Davis JJ, Silverton CD, Weir RM, Laker MW. Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial. The Journal of
41. Barrachina B, Lopez-Picado A, Remon M, Fondarella A, Iriarte I, Bastida R, et al. Tranexamic Acid Compared with Placebo for Reducing Total Blood Loss in Hip Replacement Surgery: A Randomized Clinical Trial. Anesth Analg. 2016; 122(4):986–95. Epub 2016/03/19. https://doi.org/10.1213/ANE.0000000000001159 PMID: 26991616.

42. Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty. The Journal of arthroplasty. 2014; 29(2):387–9. Epub 2013/06/25. https://doi.org/10.1016/j.arth.2013.05.026 PMID: 23790499.

43. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology. 1995; 82(2):383–92. Epub 1995/02/01. PMID: 7856897.

44. Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. The Cochrane database of systematic reviews. 2014;(11):CD006640. Epub 2014/11/22. https://doi.org/10.1002/14651858.CD006640.pub3 PubMed PMID: 25414987.

45. Astedt B, Liedholm P, Wingerup L. The effect of tranexamic acid on the fibrinolytic activity of vein walls. Ann Chir Gynaecol. 1978; 67(6):203–5. Epub 1978/01/01. PMID: 742821.